Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX
Kiora Pharmaceuticals — EyeGate Pharmaceuticals — Investor Presentation (November 2017)
12 slides from Kiora Pharmaceuticals's investor presentation, Nov 9, 2017
Slide 1: Two Versatile Platforms Moving Towards Commercialization
Two Versatile Platforms Moving Towards Commercialization
Slide 2: Forward Looking Statements
Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncerta inties, including statements relating to the prospects for the Company’s EGP - 437 and OBG product candidates, for the timing and outcome of the Company’s clin ical tria
Slide 3: Two Versatile Technology Platforms Moving Quickly to Commercialization
Expected FDA filings Second Half of 2018 3 Crosslinked Hyaluronic Acid (CMHA - S) Eye Drop Formulation in the Clinic Iontophoresis Drug Delivery System: EGP - 437 (Corticosteroid) in the Clinic Two Versatile Technology Platforms Moving Quickly to Commercialization ▪ 510K De Novo pathway with first h
Slide 4: Hyaluronic acid is a naturally occurring compound in the body
4 Hyaluronic acid is a naturally occurring compound in the body ▪ ~15 grams of HA in an adult human body ▪ Possesses unique properties such as hydration (synovial fluid) and promotion of wound healing (skin): ideal for ocular surface ▪ Issue: rapidly degrades, one - third is naturally turned - over
Slide 5: First and only eye drop candidate in the U.S. targeting re-epithelialization
First and only eye drop candidate in the U.S. targeting acceleration of re - epithelialization 5 ▪ Crosslinking creates a 3D structure that stabilizes the molecule (resists degradation) ▪ Prolonged retention time on the ocular surface (90 to 120 minutes) ▪ Higher viscosity/shear rate – thins with bl
Slide 6: First Human Clinical Trial Completed in PRK Patients
x PRK surgery provides several advantages as indication to evaluate the Ocular Bandage Gel (OBG) ▪ A homogenous patient population with same size, large epithelial defects x 39 subjects randomized to one of three groups: both eyes received the same treatment ▪ i ) OBG alone (ii) OBG + Bandage Contac
Slide 7: Corneal Wounds and Epitheliopathies: U.S. Numbers
▪ Corneal foreign bodies ▪ Abrasions / contusions ▪ Chemical burns ▪ Difficult to heal alkali burns (PCED) 7 ▪ Low concentration non - crosslinked HA eye drops are standard of care in Europe/Japan for dry eye and ocular surface damage ▪ Targeting data from next PRK trial and SPK trial in first half
Slide 8: Iontophoresis Drug Delivery Platform
x Very low electrical current supplied to electrode that repels drug into ocular tissues x Easy to use with more than 2,400 treatments already performed in office setting x Demonstrated ability to treat retinal indications with human clinical macular edema trial x Versatile platform with potential f
Slide 9: EGP-437 Licensed to Valeant (Bausch + Lomb)
Licensed to Valeant (Bausch + Lomb) to commercialize for use in the fields of ocular surgery and uveitis 9 2 to 3 treatments Up to 154 eye drop treatments VS Iontophoretic Delivery of EGP - 437 (Dexamethasone) Ensures Dosing and Reduces Patient Burden ▪ EGP - 437 being developed for 2 inflammatory c
Slide 10: Welcome to the Future of Ocular Drug Delivery
Iontophoresis and Drug Embedded in a Contact Lens 10 ▪ First indication: dexamethasone for macular edema ▪ Iontophoresis validated in clinic for retinal drug delivery ▪ In vitro work nearing completion ▪ Anticipate proof - of - concept animal data first half of 2018 ▪ Treating chronic retinal condit
Slide 11: Both Platforms Quickly Approaching FDA Filings/Commercialization
Both Platforms Quickly Approaching FDA Filings/Commercialization 11 PRK Superficial Punctate Keratitis (SPK) Important Near - Term Inflection Points First Half of 2018 Second Half of 2018 OBG: Eye Drop Iontophoresis: EGP - 437 ▪ Pilot Trial: Initiation and top - line data Anterior Uveitis Cataract S
Slide 12: Two Versatile Platforms Approaching Commercialization
12 Two Versatile Platforms Approaching Commercialization CMHA - S Platform ▪ Ocular Bandage Gel (Eye Drop): ▪ Anticipate De Novo 510(k) filing second half of 2018 for PRK and SPK ▪ Preparing for commercialization launch second half of 2019 ▪ Versatile platform with opportunities for other indication
EyeGate Pharmaceuticals — Investor Presentation (November 2017) on 6ix